Business Context and Reporting Period
Company: Eterna Therapeutics Inc. (Note: Input metadata referenced "Ernexa Therapeutics Inc.", but the filing text identifies the registrant as Eterna Therapeutics Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 20, 2025
Reporting Period: Specific event date of March 20, 2025, with funds received on March 21, 2025.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance. Key metrics include:
- New Debt Issued: $750,000 principal amount via Promissory Note.
- Interest Rate: 5.0% per annum (accrued, payable at maturity).
- Default Interest Rate: 7.0% per annum.
- Existing Related Debt: $1,500,000 promissory note issued to the same holder on March 11, 2025.
- Liquidity Impact: Company received $750,000 in cash proceeds on March 21, 2025.
- Revenue/Profit/Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes and Transaction Details
The primary material change is the entry into a Material Definitive Agreement (Item 1.01) and the creation of a Direct Financial Obligation (Item 2.03).
- Counterparty: Charles Cherington, who owns approximately 32% of the Company's outstanding common stock.
- Maturity Conditions: The note matures on the earliest of:
- June 15, 2025.
- The first business day the Company raises over $5 million in aggregate proceeds from equity, warrants, or convertible debt.
- An event of default.
- Payment Priority: Payments apply first to fees/charges, second to accrued interest, and third to principal.
Guidance, Risks, and Contingencies
Risks and Contingencies:
- Events of Default: Include failure to pay amounts due, breach of representations, failure to pay other indebtedness exceeding $50,000 after a grace period, and bankruptcy events.
- Acceleration: Upon an event of default, the holder may demand immediate repayment of all principal and accrued interest.
- Related Party Transaction: The lender is a significant shareholder (32% ownership), creating a related-party risk profile.
Guidance/Outlook: The filing text does not provide a clear value for future guidance or management commentary beyond the terms of the note.
Investor Verification Checklist
- Verify the total outstanding debt to Charles Cherington ($1,500,000 prior note + $750,000 new note = $2,250,000).
- Confirm the Company's current cash runway and ability to repay the $750,000 by June 15, 2025, or before raising $5 million in new capital.
- Review the full text of the Promissory Note (Exhibit 10.1) for specific covenants and representations not detailed in the summary.
- Assess the impact of the 32% shareholder holding a significant portion of the company's short-term debt.